JP2018510650A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510650A5 JP2018510650A5 JP2017560883A JP2017560883A JP2018510650A5 JP 2018510650 A5 JP2018510650 A5 JP 2018510650A5 JP 2017560883 A JP2017560883 A JP 2017560883A JP 2017560883 A JP2017560883 A JP 2017560883A JP 2018510650 A5 JP2018510650 A5 JP 2018510650A5
- Authority
- JP
- Japan
- Prior art keywords
- cmv
- cells
- cmv vector
- vector
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020213267A JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114203P | 2015-02-10 | 2015-02-10 | |
| US62/114,203 | 2015-02-10 | ||
| US201562196520P | 2015-07-24 | 2015-07-24 | |
| US62/196,520 | 2015-07-24 | ||
| US201562220703P | 2015-09-18 | 2015-09-18 | |
| US62/220,703 | 2015-09-18 | ||
| PCT/US2016/017373 WO2016130693A1 (en) | 2015-02-10 | 2016-02-10 | Methods and compositions useful in generating non canonical cd8+ t cell responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213267A Division JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510650A JP2018510650A (ja) | 2018-04-19 |
| JP2018510650A5 true JP2018510650A5 (cg-RX-API-DMAC7.html) | 2019-03-22 |
| JP6816031B2 JP6816031B2 (ja) | 2021-01-20 |
Family
ID=56615684
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560883A Expired - Fee Related JP6816031B2 (ja) | 2015-02-10 | 2016-02-10 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2020213267A Pending JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A Pending JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020213267A Pending JP2021121185A (ja) | 2015-02-10 | 2020-12-23 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
| JP2022126096A Pending JP2022166122A (ja) | 2015-02-10 | 2022-08-08 | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 |
Country Status (15)
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| ES2696703T3 (es) | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| CA3113595A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| CA3002922A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
| CA3028002A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| EP3539552A1 (en) * | 2018-03-16 | 2019-09-18 | Deutsches Rheuma-Forschungszentrum Berlin | Activation and expansion of nkg2c+ nk cells |
| AU2019338307A1 (en) * | 2018-09-10 | 2021-04-15 | Atara Biotherapeutics, Inc. | Methods for expanding antigen-specific CAR-T cells, compositions and uses related thereto |
| EP3941517A1 (en) * | 2019-03-21 | 2022-01-26 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US10632186B1 (en) | 2019-03-21 | 2020-04-28 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| US11077185B2 (en) | 2019-03-21 | 2021-08-03 | 21C Bio | Vaccine to pathogenic immune activation cells during infections |
| CN110055228B (zh) * | 2019-04-17 | 2023-04-28 | 华中科技大学同济医学院附属协和医院 | 用于乙肝病毒感染的重组巨细胞病毒与应用 |
| WO2020247859A2 (en) * | 2019-06-07 | 2020-12-10 | Oregon Health & Science University | Tumor-associated antigen-specific t cell responses |
| US20220307054A1 (en) * | 2019-08-20 | 2022-09-29 | Oregon Health & Science University | Modulation of t cell responses by ul18 of human cytomegalovirus |
| MX2022002270A (es) | 2019-08-29 | 2022-03-22 | Vir Biotechnology Inc | Vacunas contra el virus de la hepatitis b. |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4396208A1 (en) | 2021-08-31 | 2024-07-10 | VIR Biotechnology, Inc. | Tuberculosis vaccines |
| IL310663A (en) | 2021-08-31 | 2024-04-01 | Vir Biotechnology Inc | Recombinant hcmv vectors and uses thereof |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| DE3853139T2 (de) | 1987-06-26 | 1995-06-14 | Syntro Corp | Rekombinanter, fremde gene enthaltender menschlicher cytomegalovirus und seine verwendung. |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| SG49046A1 (en) | 1991-07-05 | 1998-05-18 | American Cyanamid Co | Method for identifying non-essential genes of the human cytomegalovirus genome and for screening for inhibitors of human cytomegaloverirus |
| WO1995003399A2 (en) | 1993-07-19 | 1995-02-02 | Cantab Pharmaceuticals Research Limited | Production method for preparation of disabled viruses |
| JPH09512177A (ja) | 1994-04-29 | 1997-12-09 | ファルマシア・アンド・アップジョン・カンパニー | ネコ免疫不全ウイルスワクチン |
| US5846806A (en) | 1994-07-29 | 1998-12-08 | American Cyanamid Company | Identification of a human cytomegalovirus gene region involved in down-regulation of MHC class I heavy chain expression |
| AU711121B2 (en) | 1995-02-21 | 1999-10-07 | Cantab Pharmaceuticals Research Limited | Viral preparations, vectors, immunogens, and vaccines |
| JPH11503024A (ja) | 1995-04-04 | 1999-03-23 | セル・ジェネシス・インコーポレイテッド | 細胞表面のクラスｉ ｍｈｃタンパク質の低レベルを有する遺伝子学的に修飾された細胞の移植 |
| ES2237800T3 (es) | 1996-07-31 | 2005-08-01 | Ortho-Mcneil Pharmaceutical, Inc. | Identificacion de genes del citomegalovirus humano implicados en la retro-regulacion de la expresion de las cadenas pesadas de la clase i del cmh. |
| US20030138454A1 (en) | 1997-06-09 | 2003-07-24 | Oxxon Pharmaccines, Ltd. | Vaccination method |
| DE19733364A1 (de) | 1997-08-01 | 1999-02-04 | Koszinowski Ulrich H Prof | Verfahren zur Klonierung eines großen Virusgenoms |
| WO1999007869A1 (en) | 1997-08-05 | 1999-02-18 | University Of Florida | Live recombinant vaccine comprising inefficiently or non-replicating virus |
| US7204990B1 (en) | 2000-11-28 | 2007-04-17 | Medimmune Vaccines, Inc. | Attenuation of cytomegalovirus virulence |
| WO2002062296A2 (en) | 2001-02-02 | 2002-08-15 | Chemocentryx, Inc. | Methods and compositions useful for stimulating an immune response |
| WO2002066629A2 (en) | 2001-02-21 | 2002-08-29 | Gabriele Hahn | Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates |
| GB0122232D0 (en) | 2001-09-14 | 2001-11-07 | Medical Res Council | Gene expression |
| IL160809A0 (en) | 2001-09-20 | 2004-08-31 | Glaxo Group Ltd | HIV-gag CODON-OPTIMISED DNA VACCINES |
| US20030118568A1 (en) | 2001-12-18 | 2003-06-26 | Board Of Trustees Of The University Of Arkansas | Viral stealth technology to prevent T cell-mediated rejection of xenografts |
| JP2005523942A (ja) | 2002-04-30 | 2005-08-11 | アヴィオル セラピューティクス インコーポレイテッド | 免疫療法のためのアデノウイルスベクター |
| DE10232322A1 (de) | 2002-07-16 | 2004-07-29 | Hahn, Gabriele, Dr. | Viral kodierte CxC determinieren den Gewebetropismus von HCMV |
| US7407744B2 (en) | 2003-07-25 | 2008-08-05 | The Regents Of The University Of California | Cytomegalovirus gene function and methods for developing antivirals, anti-CMV vaccines, and CMV-based vectors |
| EP2497831B1 (en) | 2004-05-25 | 2014-07-16 | Oregon Health and Science University | TB vaccination using HCMV-based vaccine vectors |
| EP1602676A1 (en) | 2004-06-01 | 2005-12-07 | SOLVAY (Société Anonyme) | Catalytic compositions |
| WO2006004661A1 (en) | 2004-06-25 | 2006-01-12 | Medimmune Vaccines, Inc. | Recombinant human cytomegalovirus and vaccines comprising heterologous antigens |
| EP1888622A1 (en) | 2005-05-23 | 2008-02-20 | Oxxon Therapeutics Ltd. | Compositions for inducing an immune response against hepatitis b |
| BRPI0615400A2 (pt) | 2005-08-31 | 2011-05-17 | Genvec Inc | vacinas para malária baseadas em vetor adenoviral |
| US20100142823A1 (en) | 2007-03-07 | 2010-06-10 | Ze Wang | 2d partially parallel imaging with k-space surrounding neighbors based data reconstruction |
| CA2754826A1 (en) | 2009-03-06 | 2010-09-10 | Mount Sinai School Of Medicine | Live attenuated influenza virus vaccines comprising microrna response elements |
| MX2012007489A (es) | 2009-12-23 | 2012-11-29 | 4Antibody Ag | Miembros enlazadores para citomegalovirus. |
| EP2529227B1 (en) | 2010-01-27 | 2015-10-07 | Oregon Health & Science University | Cytomegalovirus-based immunogenic preparations |
| CA2793959C (en) | 2010-03-25 | 2019-06-04 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| JP2013527758A (ja) | 2010-05-05 | 2013-07-04 | ティリオン，クリスティアン | ベータヘルペスウイルス感染に対するワクチンおよびその使用 |
| SI2772265T1 (en) | 2010-05-14 | 2018-06-29 | Oregon Health & Science University | HCMV AND RHCMV RECOMBINANT VECTORS AND THEIR APPLICATIONS |
| SI2691530T1 (en) | 2011-06-10 | 2018-08-31 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
| ES2696703T3 (es) | 2013-03-05 | 2019-01-17 | Univ Oregon Health & Science | Vectores de citomegalovirus que permiten el control del direccionamiento de los linfocitos T |
| CA3113595A1 (en) | 2014-07-16 | 2016-01-21 | Oregon Health & Science University | Human cytomegalovirus comprising exogenous antigens |
| EP3048114A1 (en) | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
| KR20170136512A (ko) | 2015-02-10 | 2017-12-11 | 오레곤 헬스 앤드 사이언스 유니버시티 | 넌-캐노니컬 cd8+ t 세포 반응 생성에 유용한 방법 및 조성물 |
| CA3005136A1 (en) | 2015-11-20 | 2017-05-26 | Oregon Health & Science University | Cmv vectors comprising microrna recognition elements |
| AU2017280065B2 (en) | 2016-06-22 | 2021-07-01 | International Aids Vaccine Initiative, Inc. | Recombinant cytomegalovirus vectors as vaccines for tuberculosis |
| CA3028002A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
| CA3040303A1 (en) | 2016-10-18 | 2018-04-26 | Oregon Health & Science University | Cytomegalovirus vectors eliciting t cells restricted by major histocompatibility complex e molecules |
-
2016
- 2016-02-10 KR KR1020177025544A patent/KR20170136512A/ko not_active Ceased
- 2016-02-10 EP EP16749813.8A patent/EP3256595A4/en not_active Withdrawn
- 2016-02-10 WO PCT/US2016/017373 patent/WO2016130693A1/en not_active Ceased
- 2016-02-10 MA MA041756A patent/MA41756A/fr unknown
- 2016-02-10 HK HK18106974.7A patent/HK1247638A1/zh unknown
- 2016-02-10 CN CN202111437865.0A patent/CN114317611A/zh active Pending
- 2016-02-10 JP JP2017560883A patent/JP6816031B2/ja not_active Expired - Fee Related
- 2016-02-10 CA CA2976245A patent/CA2976245A1/en not_active Abandoned
- 2016-02-10 SG SG11201706454VA patent/SG11201706454VA/en unknown
- 2016-02-10 US US15/549,814 patent/US20180298404A1/en not_active Abandoned
- 2016-02-10 MX MX2017010027A patent/MX2017010027A/es unknown
- 2016-02-10 AU AU2016219317A patent/AU2016219317A1/en not_active Abandoned
- 2016-02-10 EA EA201791806A patent/EA201791806A1/ru unknown
- 2016-02-10 HK HK18113013.6A patent/HK1254041A1/zh unknown
- 2016-02-10 CN CN201680014682.9A patent/CN108064304A/zh active Pending
- 2016-02-10 BR BR112017017092A patent/BR112017017092A2/pt not_active Application Discontinuation
- 2016-02-10 EP EP21205026.4A patent/EP4036239A1/en not_active Withdrawn
-
2017
- 2017-08-09 IL IL253935A patent/IL253935B/en unknown
-
2020
- 2020-01-09 US US16/738,178 patent/US11091779B2/en not_active Expired - Fee Related
- 2020-12-23 JP JP2020213267A patent/JP2021121185A/ja active Pending
-
2022
- 2022-08-08 JP JP2022126096A patent/JP2022166122A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510650A5 (cg-RX-API-DMAC7.html) | ||
| Humphreys et al. | Novel viral vectors in infectious diseases | |
| O’Hara et al. | Memory T cell inflation: understanding cause and effect | |
| Schleiss et al. | Progress toward development of a vaccine against congenital cytomegalovirus infection | |
| Cohen | Vaccine development for Epstein-Barr virus | |
| Khanna et al. | Human cytomegalovirus vaccine: time to look for alternative options | |
| La Rosa et al. | MVA vaccine encoding CMV antigens safely induces durable expansion of CMV-specific T cells in healthy adults | |
| van Zyl et al. | Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice | |
| Sung et al. | Update on the current status of cytomegalovirus vaccines | |
| JP6816031B2 (ja) | 非標準的なｃｄ８＋ｔ細胞応答を生成するのに有用な方法および組成物 | |
| King et al. | A whole recombinant yeast-based therapeutic vaccine elicits HBV X, S and Core specific T cells in mice and activates human T cells recognizing epitopes linked to viral clearance | |
| Farrington et al. | Competition for antigen at the level of the APC is a major determinant of immunodominance during memory inflation in murine cytomegalovirus infection | |
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| Schermuly et al. | In vitro model for lytic replication, latency, and transformation of an oncogenic alphaherpesvirus | |
| Dubensky Jr et al. | Delivery systems for gene-based vaccines | |
| JP2019502371A5 (cg-RX-API-DMAC7.html) | ||
| JP2019531745A5 (cg-RX-API-DMAC7.html) | ||
| Khan et al. | Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes | |
| JP2019511921A5 (cg-RX-API-DMAC7.html) | ||
| Souquette et al. | Past life and future effects—how heterologous infections alter immunity to influenza viruses | |
| Forrest et al. | NK cell memory to cytomegalovirus: implications for vaccine development | |
| Fiedler et al. | Prime/boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus | |
| Abdelaziz et al. | Development of a human cytomegalovirus (HCMV)-based therapeutic cancer vaccine uncovers a previously unsuspected viral block of MHC class I antigen presentation | |
| Macdonald et al. | Harnessing alveolar macrophages for sustained mucosal T-cell recall confers long-term protection to mice against lethal influenza challenge without clinical disease | |
| Zhong et al. | Vaccine strategies against human cytomegalovirus infection |